FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2573020009> ?p ?o ?g. }

• W2573020009 abstract "Abstract Abstract 722 Immunomodulating monoclonal antibodies (mAb) directed against immune cell targets can be used to enhance antitumor immune responses. CD137 (4-1BB) is a costimulatory molecule expressed on a variety of activated immune cells, including T and NK cells. Anti-CD137 agonistic mAb has demonstrated antitumor activity in various tumor models and has now entered clinical trials for the treatment of solid tumors (BMS-663513). Here, we investigate the therapeutic potential of anti-CD137 mAb in lymphoma. Using microarray gene expression data, we compared CD137 mRNA expression across 17 different types of cancer. We found that lymphoma tumor specimens significantly over-expressed CD137 mRNA compared to other tumors (p<0.0001). Single cell analysis of primary lymphoma samples of various histologies (follicular lymphoma [n=29], mantle cell lymphoma [n=14], and diffuse large B cell lymphoma [n=11]) revealed that CD137 was expressed by a significant proportion of tumor-infiltrating T cells, particularly in the CD8 subset (mean[range]=6.1%[2.5-11.5], 15.4%[2.7-40.9] and 18.7%[6.7-51.7], respectively). In contrast, CD137 was not expressed by the tumor cells. These results suggest that the target of anti-CD137 mAb is present and selectively expressed on cells with potential antitumor activity in patients with lymphoma. Using a murine model, we then investigated the anti-lymphoma activity of anti-CD137 agonistic mAb in vivo. BALB/c mice, bearing large and established A20 lymphoma tumors, were treated with anti-CD137 mAb or other immunomodulating mAbs (anti-OX40, anti-CTLA4, anti-GITR) for comparison. The mAbs were given i.p. on days 5 and 10 post tumor inoculation. Anti-CD137 mAb demonstrated potent anti-lymphoma activity in vivo, and appeared to be significantly superior to the other immunomodulating mAbs tested (Figure 1). The antitumor effect of anti-CD137 mAb was not due to direct targeting of the malignant cells as A20 tumor cells do not express CD137. Depletion experiments revealed that anti-CD137 therapy required both NK and CD8 T cells. Analysis of tumor-bearing mice showed that anti-CD137 therapy increased the number of CD8 T cells and reduced the number of Tregs at the tumor site. Anti-CD137 therapy also induced long-lasting antitumor immunity as cured mice harbored antitumor IFN-g producing memory CD8 T cells and were protected from tumor re-challenge more than 100 days after initial therapy. In conclusion, this study demonstrates for the first time that anti-CD137 agonistic mAb has potent antitumor activity in lymphoma. These results support the evaluation of anti-CD137 mAb in clinical trials for patients with lymphoma. Disclosures: No relevant conflicts of interest to declare." @default.
• W2573020009 created "2017-01-26" @default.
• W2573020009 creator A5004859097 @default.
• W2573020009 creator A5007420876 @default.
• W2573020009 creator A5013118738 @default.
• W2573020009 creator A5031216970 @default.
• W2573020009 creator A5035295243 @default.
• W2573020009 creator A5044260568 @default.
• W2573020009 creator A5052061341 @default.
• W2573020009 creator A5055927975 @default.
• W2573020009 creator A5077678938 @default.
• W2573020009 creator A5083342021 @default.
• W2573020009 creator A5090605318 @default.
• W2573020009 date "2009-11-20" @default.
• W2573020009 modified "2023-09-29" @default.
• W2573020009 title "Therapeutic Potential of Anti-CD137 Antibody in Lymphoma." @default.
• W2573020009 doi "https://doi.org/10.1182/blood.v114.22.722.722" @default.
• W2573020009 hasPublicationYear "2009" @default.
• W2573020009 type Work @default.
• W2573020009 sameAs 2573020009 @default.
• W2573020009 citedByCount "0" @default.
• W2573020009 crossrefType "journal-article" @default.
• W2573020009 hasAuthorship W2573020009A5004859097 @default.
• W2573020009 hasAuthorship W2573020009A5007420876 @default.
• W2573020009 hasAuthorship W2573020009A5013118738 @default.
• W2573020009 hasAuthorship W2573020009A5031216970 @default.
• W2573020009 hasAuthorship W2573020009A5035295243 @default.
• W2573020009 hasAuthorship W2573020009A5044260568 @default.
• W2573020009 hasAuthorship W2573020009A5052061341 @default.
• W2573020009 hasAuthorship W2573020009A5055927975 @default.
• W2573020009 hasAuthorship W2573020009A5077678938 @default.
• W2573020009 hasAuthorship W2573020009A5083342021 @default.
• W2573020009 hasAuthorship W2573020009A5090605318 @default.
• W2573020009 hasConcept C159654299 @default.
• W2573020009 hasConcept C167672396 @default.
• W2573020009 hasConcept C203014093 @default.
• W2573020009 hasConcept C2779338263 @default.
• W2573020009 hasConcept C2780249625 @default.
• W2573020009 hasConcept C502942594 @default.
• W2573020009 hasConcept C542903549 @default.
• W2573020009 hasConcept C86803240 @default.
• W2573020009 hasConcept C8891405 @default.
• W2573020009 hasConceptScore W2573020009C159654299 @default.
• W2573020009 hasConceptScore W2573020009C167672396 @default.
• W2573020009 hasConceptScore W2573020009C203014093 @default.
• W2573020009 hasConceptScore W2573020009C2779338263 @default.
• W2573020009 hasConceptScore W2573020009C2780249625 @default.
• W2573020009 hasConceptScore W2573020009C502942594 @default.
• W2573020009 hasConceptScore W2573020009C542903549 @default.
• W2573020009 hasConceptScore W2573020009C86803240 @default.
• W2573020009 hasConceptScore W2573020009C8891405 @default.
• W2573020009 hasLocation W25730200091 @default.
• W2573020009 hasOpenAccess W2573020009 @default.
• W2573020009 hasPrimaryLocation W25730200091 @default.
• W2573020009 hasRelatedWork W1971730021 @default.
• W2573020009 hasRelatedWork W1978704906 @default.
• W2573020009 hasRelatedWork W1980471102 @default.
• W2573020009 hasRelatedWork W1992979622 @default.
• W2573020009 hasRelatedWork W2030204783 @default.
• W2573020009 hasRelatedWork W2037658469 @default.
• W2573020009 hasRelatedWork W2045756560 @default.
• W2573020009 hasRelatedWork W2049133947 @default.
• W2573020009 hasRelatedWork W2073880277 @default.
• W2573020009 hasRelatedWork W2107335150 @default.
• W2573020009 hasRelatedWork W2111506773 @default.
• W2573020009 hasRelatedWork W2147931798 @default.
• W2573020009 hasRelatedWork W2327409939 @default.
• W2573020009 hasRelatedWork W2384027871 @default.
• W2573020009 hasRelatedWork W2556167380 @default.
• W2573020009 hasRelatedWork W2581749833 @default.
• W2573020009 hasRelatedWork W2588629939 @default.
• W2573020009 hasRelatedWork W2618705717 @default.
• W2573020009 hasRelatedWork W3199514812 @default.
• W2573020009 hasRelatedWork W2098562115 @default.
• W2573020009 isParatext "false" @default.
• W2573020009 isRetracted "false" @default.
• W2573020009 magId "2573020009" @default.
• W2573020009 workType "article" @default.